Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)

Cancer Prevention Research

Volumn 5, Issue 11, 2012, Pages 1321-1329

  Cecchini, Reena S ^a,b   Costantino, Joseph P ^a,b   Cauley, Jane A ^b   Cronin, Walter M ^a,b   Wickerham, D Lawrence ^a,c   Bandos, Hanna ^a,b   Weissfeld, Joel L ^d   Wolmark, Norman ^a,c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; CARCINOMA; CELL COUNT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TAMOXIFEN;

EID: 84870184047     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0273     Document Type: Article

References (38)

1. American Cancer Society. Global cancer facts & figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011.
2. Breast cancer risk assessment tool [Internet]; 2008 [updated 2011 May 16; cited 2012 Feb 7]. Available from: http://www.cancer.gov/bcrisktool.
3. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. (Pubitemid 20026073)
4. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8. (Pubitemid 29457958)
5. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66. (Pubitemid 32229380)
6. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007;99:1782-92. (Pubitemid 351767204)
7. Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst 2011;1032:951-61.
8. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337-47. (Pubitemid 351665464)
9. Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-95. (Pubitemid 47073482)
10. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 2010;102:1224-37.
11. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-26. (Pubitemid 44390992)
12. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-14. (Pubitemid 44390991)
13. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115-22. (Pubitemid 41547108)
14. D'Orsi CJ, Bassett LW, Berg WA, et al. BI-RADS: mammography. 4th ed. In:D'Orsi CJ, Mendelson EB, Ikeda DM, et al. Breast Imaging Reporting and Data System: ACR BI-RADS - breast imaging atlas. Reston, VA: American College of Radiology; 2003. Frequently Asked Questions, pages 3-4; http://www.acr.org/~/ media/ACR/Documents/PDF/QualitySafety/Resources/BIRADS/BIRADSFAQs.pdf Accessed 10-16-12.
15. Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA. Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 2006;13:1143-9. (Pubitemid 44279450)
16. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13:223.
17. Anderson BO. Prophylactic surgery to reduce breast cancer risk: a brief literature review. Breast J 2001;7:321-30. (Pubitemid 33101637)
18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
19. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
20. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:384-98.
21. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007;99:1695-705. (Pubitemid 351767220)
22. Gail MH, Anderson WF, Garcia-Closas M, Sherman ME. Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst 2007;99:1657-9. (Pubitemid 351767222)
23. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
24. Martin KE, Helvie MA, Zhou C, Roubidoux MA, Bailey JE, Paramagul C, et al. Mammographic density measured with quantitative computer-aided method: comparison with radiologists' estimates and BI-RADS categories. Radiology 2006;240:656-65. (Pubitemid 44267320)
25. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44. (Pubitemid 30422619)
26. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011;30:1105-17.
27. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105. (Pubitemid 40380968)
28. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8. (Pubitemid 38584986)
29. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011;103:744-52.
30. Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
31. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6. (Pubitemid 29508720)
32. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-90. (Pubitemid 38657490)
33. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-5.
34. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230:29-41. (Pubitemid 37549780)
35. Lokate M, Kallenberg MG, Karssemeijer N, Van den Bosch MA, Peeters PH, Van Gils CH. Volumetric breast density from full-field digital mammograms and its association with breast cancer risk factors: a comparison with a threshold method. Cancer Epidemiol Biomarkers Prev 2010;19:3096-105.
36. Stone J, Warren RM, Pinney E, Warwick J, Cuzick J. Determinants of percentage and area measures of mammographic density. Am J Epidemiol 2009;170:1571-8.
37. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:2086-92. (Pubitemid 44877030)
38. Vachon CM, Brandt KR, Ghosh K, Scott CG, Maloney SD, Carston MJ, et al. Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:43-9. (Pubitemid 46174262)